Fig. 2: Time-to-treatment failure according to HER2 PET/CT alone, early FDG PET/CT alone, and a combination of the HER2 PET/CT and early FDG PET/CT. | npj Breast Cancer

Fig. 2: Time-to-treatment failure according to HER2 PET/CT alone, early FDG PET/CT alone, and a combination of the HER2 PET/CT and early FDG PET/CT.

From: Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

Fig. 2

a Early FDG PET/CT alone (b) combination of the HER2 PET/CT and early FDG PET/CT (c). a HER2-positive pattern (blue line): patients with pattern A and B for HER2 uptake; HER2-negative pattern (red line): patients with pattern C and D for HER2 uptake. b Patients with early metabolic response on FDG PET/CT (response, blue line); patients without early metabolic response on FDG PET/CT (no response, red line). c Patients with positive pattern on HER2 PET/CT showing early metabolic response on FDG PET/CT (blue line); patients with negative pattern on HER2 PET/CT without early metabolic response on FDG PET/CT (green line); patients with positive pattern on HER2 PET/CT and early nonresponse or vice versa (discordant cases) (red line).

Back to article page